BioHarvest Sciences Inc. has raised its forecast of 2021 annual sales orders for VINIA in Israel, saying the continued adoption of VINIA in Israel demonstrates the health benefits and efficacy of the product.
The company has increased its 2021 sales orders forecast for Israel to US$1.6 million-US$1.7 million from the previous forecast of US$1.3 million-US$1.5 million announced in March 2021.
BioHarvest said the high percentage of revenue from returning customers validates their loyalty to the product, while the combination of increased transactions and the increased value of each order is fueling revenue growth.
Next January, the company said it will provide a sales orders forecast calendar for the year 2022.
READ: BioHarvest Sciences banks strong 3Q on increasing sales of its flagship VINIA product in Israel and the US
In a statement, Ilan Sobel, the BioHarvest CEO, commented: "The 15% increase in the Company's forecast is a testimonial to the quality and efficacy of VINIA and to its ability to reach customers. We are constantly improving our methods to reach out to customers and build a strong base of loyal consumers. I look forward to the continued growth in sales orders and to bringing new products to the market in 2022."
Q3 Shareholder Update
BioHarvest also invited interested investors and media to its next Shareholder Update, to be held at 11.00am PST on October 14, 2021. The online meeting will be hosted by CEO Sobel, and will feature a live Question and Answer session. Registeration is at: https://app.livestorm.co/st-financial/october-2021-bhsc-shareholder-update?type=detailed. Investors not available to attend live, can still register and will be send a session recording after the event.
BioHarvest Sciences has developed a patented bio-cell growth platform technology capable of growing the active and beneficial ingredients in fruit and plants, at industrial scale, without the need to grow the plant itself. The technology is economical, ensures consistency, and avoids the negative environmental impacts associated with traditional agriculture. BioHarvest is currently focused on nutraceuticals and the medicinal cannabis markets.
Contact the author at jon.hopkins@proactiveinvestors.com